Teva announces launch of a generic version of nuvaring® (etonogestrel and ethinyl estradiol) vaginal ring in the united states

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals usa, inc., a u.s. affiliate of teva pharmaceutical industries ltd.(nyse and tase: teva), today announced the availability of a generic version of nuvaring®1 (etonogestrel and ethinyl estradiol vaginal ring), 0.120 mg/0.015 mg per day, in the u.s. teva's ab-rated and bioequivalent etonogestrel and ethinyl estradiol vaginal ring, is an estrogen/progestin combination hormonal contraceptive (chc) indicated for use by women t
TEVA Ratings Summary
TEVA Quant Ranking